Bioceres Crop Solutions Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOX research report →
Range $2 – $15
Price Chart
About the company
Bioceres Crop Solutions Corp. (BIOX) is a company dedicated to enhancing agricultural output through a diverse range of solutions. Its operations are organized into three principal divisions.
- CEO
- Federico Trucco
- IPO
- 2018
- Employees
- 751
- HQ
- Rosario, SF, AR
Get TickerSpark's AI analysis on BIOX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $28.12M
- P/E
- -0.12
- Fwd P/E
- 8.90
- PEG
- -0.00
- P/S
- 0.11
- P/B
- 0.45
- EV/EBITDA
- -12.63
- Div Yield
- 0.00%
- Gross Margin
- 36.71%
- Op Margin
- 0.82%
- Net Margin
- -95.02%
- ROE
- -154.24%
- ROIC
- 0.55%
Latest fiscal year · YoY change
- Revenue
- $333.34M-28.3%
- Gross Profit
- $128.15M-29.4%
- Op Income
- $-761,904
- Net Income
- $-55,416,054-1808.8%
- EPS
- $-0.82-1689.1%
- OCF Growth
- +19.6%
- FCF Growth
- +86.4%
- 52W High
- $3.07
- 52W Low
- $0.30
- 50D MA
- $0.37
- 200D MA
- $0.77
- Beta
- 0.40
- RSI (14)
- 66
- Avg Volume
- 207.13K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Bioceres reported a weak fiscal third quarter with lower revenue, gross profit and EBITDA, while management emphasized liquidity preservation, portfolio simplification, and legal/financial restructuring efforts.· May 12, 2026
- Revenue fell 23% year over year to $39.4 million, led by declines in Crop Protection and a 71% drop in Seeds and Integrated Products.
- Gross profit declined 30% year over year to $12.7 million, with gross margin down from 35% to 32% due to mix and an inoculant obsolescence adjustment.
- Adjusted EBITDA was negative $0.6 million versus positive $9.1 million last year, with the prior-year quarter benefiting from $7.7 million of nonrecurring other income.
- The company highlighted ongoing transition away from downstream seed and grain sales toward a more asset-light model, alongside a strategic review of continuing operations.
- Management is focused on collections, working capital discipline, liability management, and preserving liquidity amid the Pro Farm litigation and debt reprofiling efforts.
Total revenues were $39.4 million, down 23% year over year. Gross profit was $12.7 million versus $18.1 million a year ago, and gross margin declined from 35% to 32%. Adjusted EBITDA was negative $0.6 million compared with positive $9.1 million in the prior-year quarter. Crop Protection revenue was $24.6 million, down 18%; Seeds and Integrated Products revenue declined 71%; and Crop Nutrition revenue increased 15% to $11.6 million. As of March 31, 2026, total financial debt was approximately $229 million, cash/cash equivalents/short-term investments were approximately $14 million, and net financial debt was approximately $214 million. Management did not give next-quarter or full-year financial guidance on the call. Instead, it said it is prioritizing liquidity preservation, working capital discipline, tighter capital allocation, and a reprofiling process for Rizobacter debt in Argentina, while continuing to dispute the noteholder litigation and foreclosure process.
Federico Trucco framed the quarter as a transition period and said the business is being refocused around discipline, simplification, and cash preservation. He stressed that the company is advancing organizational streamlining, working capital management, cash generation initiatives, and a strategic review of continuing operations and capital allocation. His tone was cautious, with repeated references to market challenges, uncertainty from the litigation, and the need to stabilize the platform.
Ezequiel Simmermacher emphasized the financial impact of the Pro Farm foreclosure: about $194 million of net assets were recognized or reclassified, offset by the $15 million credit bid, resulting in an accumulated noncash loss of approximately $179 million. He said debt was approximately $229 million, cash and short-term investments about $14 million, and net financial debt about $214 million, all broadly stable sequentially, while substantially all related debt is now classified as short term after the acceleration notice. He also noted lower operating expenses from cost controls and streamlining, improved JV results, and the ongoing focus on liquidity, receivables collection, and capital allocation.
The only analyst question focused on collections and operating cash flow. Management said it is pushing receivables lower by offering customers incentives to advance collections and by using shorter terms on new sales during lower sell periods. When asked for operating cash flow for the quarter and year to date, management did not provide the number on the call and said it could be shared later, which reinforced the lack of detailed cash-flow disclosure in the prepared remarks.
The bullish case from this call is that Bioceres is actively shrinking lower-margin, working-capital-intensive activities while pushing its crop nutrition business, which grew 15% year over year in the quarter. Management also said operating expenses improved meaningfully through cost control and streamlining, and that joint ventures contributed positively to EBITDA. If those operational simplification and collections efforts continue, the company could improve liquidity and financial flexibility even in a difficult market.
The bear case is that the quarter showed broad weakness: revenue fell 23%, gross profit fell 30%, and adjusted EBITDA turned slightly negative, while Seeds and Integrated Products continues to shrink sharply. The company is still dealing with major litigation over the Pro Farm foreclosure and has substantial debt, with most related debt now classified as short term after an acceleration notice. Management also did not provide operating cash flow figures on the call, which leaves investors with limited visibility into near-term cash generation.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 70.1%
- Shares Outstanding
- 63.23M
- Float Shares
- 44.33M
of shares held by institutions
31 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Solel Partners LP | 4.58M | 0 |
| Mirae Asset Global Etfs Holdings Ltd. | 1.41M | ▲ 332.64K |
| Long Focus Capital Management, LLC | 829.75K | 0 |
| Ardsley Advisory Partners LP | 475.00K | 0 |
| Ubs Group AG | 408.28K | ▲ 50.12K |
| Susquehanna International Group, Llp | 212.93K | ▼ 2.46K |
| Pnc Financial Services Group, Inc. | 133.00K | 0 |
| Goldman Sachs Group Inc | 129.44K | ▲ 12.57K |
| Ping Capital Management, Inc. | 55.00K | 0 |
| Jane Street Group, LLC | 36.27K | ▲ 2.16K |
| Two Sigma Investments, LP | 30.03K | ▼ 65.29K |
| Stifel Financial Corp | 29.59K | ▼ 53.50K |
Held by 1 ETFs
Biggest fund positions in BIOX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 20, 26 | Trucco Federico | other | 130,000 |
| May 20, 26 | Trucco Federico | other | 150,000 |
| Aug 3, 26 | Simmermacher Ezequiel | other | 375,000 |
| Jun 30, 28 | Duraiswami Narain | other | 150,000 |
| Jan 5, 26 | Simmermacher Ezequiel | other | 0 |
| Jul 12, 22 | Mago Yogesh | other | 0 |
| Mar 13, 19 | Trucco Federico | other | 0 |
| Apr 24, 19 | Trucco Federico | other | 300,000 |
| Jun 30, 25 | Trucco Federico | other | 500,000 |
| Apr 1, 21 | Roque Jose Augusto | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BIOX coverage
Recent articles, reports, and earnings notes.
No research on BIOX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIOX report →Pinnacle Food Group (NASDAQ:PFAI) vs. Bioceres Crop Solutions (NASDAQ:BIOX) Head to Head Contrast
defenseworld.net · Jul 22
Bioceres Crop Solutions Corp. (BIOX) Q3 2026 Earnings Call Transcript
seekingalpha.com · May 12
Bioceres Crop (BIOX) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · May 11
Bioceres Crop Solutions Reports Fiscal Third Quarter 2026 Financial and Operational Results
businesswire.com · May 11
CORRECTING and REPLACING Bioceres Crop Solutions to Host Fiscal Third Quarter 2026 Financial Results Conference Call on Tuesday, May 12, 2026 at 8:30 a.m. Eastern Time
businesswire.com · May 5
Bioceres Crop Solutions to Host Fiscal Third Quarter 2026 Financial Results Conference Call on Tuesday, May 12, 2026 at 8:30 a.m. Eastern Time
businesswire.com · May 4
Bioceres Crop Solutions (NASDAQ:BIOX) and Lavoro (NASDAQ:LVRO) Financial Comparison
defenseworld.net · Apr 6
Head-To-Head Review: Bioceres Crop Solutions (NASDAQ:BIOX) and Moolec Science (NASDAQ:MLEC)
defenseworld.net · Apr 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.